Update from Shield Therapeutics CEO Anders Lundstrom & CFO Santosh Shanbhag hosted a live session on FY 2024 audited results + Q1 2025 trading update. 📺 Replay now via: shieldtherapeutics.com

We are excited to share that Santosh Shanbhag, CFO will be presenting at BIO2025 in Boston. Join Santosh as he provides an overview of Shield Therapeutics on 17 June 2025 at 11am (Room 153B). We look forward to seeing you there. #BIO2025 #ShieldTherapeutics

Our CFO, Santosh Shanbhag and our VP of Manufacturing and Strategic Alliance, David Childs visited with our partners - Jiangsu Aosaikang Pharmaceutical Co., Ltd. (ASK) to discuss and further develop our partnership and support ASK as they prepare to submit the NDA in China.

Wrapping up the final day in Boston at BIO 2025. We had a fantastic turnout for our presentation and were fortunate to connect with so many inspiring professionals driving the future of biotech.

Thank you, VITAL-NET, for your incredible hospitality in Japan. It was an honour to visit your team and celebrate the official signing of our exclusive licence agreement, here’s to a successful and collaborative future bringing ACCRUFeR to the Japanese market.

Please join Shield in welcoming Antonio Monteiro, who joined the team this week as Director of Regulatory Affairs. Antonio will manage the operational and strategic responsibilities for Regulatory Affairs and will report into the VP Quality, Clinical and Regulatory Affairs.

Our US office will be closed today as we celebrate Independence Day. We would like to wish everyone a safe and meaningful 4th of July.

Jason is a key member of the sales team here at Shield. Please join us in congratulating Jason on this well earned promotion. #TeamShield #STX

Please join us in welcoming the newest members of our team to join Shield in Q2 2025. We are excited to welcome our newest recruits as we continue to grow and strengthen our capabilities within our commercial team in the US. #WelcomeToTheTeam #STX #TeamShield

$STX Positive 2Q'25 update from Shield Therapeutics with US #Accrufer Rx above forecast at 47k (45k est), up 28% over 1Q'25, and at a better average price $231 ($225 est). Cash position also stronger at $10.8m. Augurs well to reach cashflow breakeven by year-end. shieldtherapeutics.com/investors-and-…

$STX Shield Therapeutics shares surge 21% as ACCRUFeR revenues double tinyurl.com/2cvhs366 Shield Therapeutics $SHIEF #STX #SHIEF

Shield Therapeutics shares surge 21% as ACCRUFeR revenues double Shield Therapeutics #AIM #OTCQB #STX #SHIEF ow.ly/wt9X106gFc3

Shield Therapeutics plc eported a substantial increase in Group revenues, ACCRUFeR® prescription sales and average net selling price.  The Company remains on track to achieve its prior guidance of turning cash flow positive by the end of 2025.

The US Food and Drug Administration (FDA) has accepted ACCRUFeR®/FeRACCRU® (ferric maltol) as a Clinical Supplement and assigned Priority Review to extend the indication  to include adolescents aged 10 years and above. For full details visit shieldtherapeutics.com

We are always interested in discussing new opportunities to collaborate and expand our global reach. Please contact us for more details on your area of interest. Global Partners | Shield Therapeutics plc

We are excited to be exhibiting at #AAFPFMX, October 5–9 in Anaheim, CA. Visit us at Booth 1683 to see how Shield Therapeutics is supporting family physicians on the frontlines of care. 👉 Learn more and register: i.snoball.it/p/iZ4HF/l

We are looking forward to attending #BIOEurope! Join Shield Therapeutics in Vienna, Austria, November 3–5, 2025 or connect with the team via partnering. We look forward to seeing you there.

The Shield team had a great experience at BIO-Europe 2025. It was a pleasure connecting with so many industry professionals and exploring new opportunities for collaboration. A big thank you to everyone we met, we look forward to staying in touch and continuing the conversations.

Shield Therapeutics plc is pleased to announce that the Korean Ministry of Food and Drug Safety has granted regulatory approval for ACCRUFeR® in the Republic of Korea for the treatment of iron deficiency in adult subjects. For full details visit shieldtherapeutics.com/news/